The use of blood transfusions and erythropoietin-stimulating agents in Swedish palliative care
The use of blood transfusions and erythropoietin-stimulating agents in Swedish palliative care
复制标题
DOI：
10.1007/s00520-008-0499-9
复制
发表时间：
2009-02-01
影响因子：
3.1
通讯作者：
Lundstrom, Staffan
中科院分区：
文献类型：
--
作者：
Martinsson, Ulla;Lundstrom, Staffan
为了概述输血和促红细胞生成素刺激剂（ESA）在瑞典姑息治疗中的使用，并了解这些通常病情严重的患者是否从治疗中受益，瑞典姑息治疗研究网络内的24个专业姑息治疗单位发出了一份基于互联网的问卷。所有数据由每个成员直接登记到一个基于网络的调查生成器中，从中提取结果并进行分析。22个单位登记了1,046名患者（中位年龄68岁，87%有癌症诊断）。在这些患者中，900人参加了高级家庭护理，其他人在住院单位接受治疗。在登记前一个月内，174例患者（17%）接受了红细胞输注，平均每例患者输注量为2.9单位（范围1-18）。18%的恶性肿瘤患者和11%的非恶性疾病患者接受了红细胞输注。6名患者还接受了血小板输注。117例患者（68%）被判定从红细胞输注中获益。82（58%）的141名输血患者参加了先进的家庭护理在他们的家中接受输血。127名患者（12%）接受了ESA治疗。在瑞典的姑息治疗中，输血并不罕见。大多数人似乎从输血中受益。由于它们既昂贵又耗时，因此应在每个人身上仔细评估效果，以避免无效治疗。
To outline the use of blood transfusions and erythropoietin-stimulating agents (ESAs) in palliative care in Sweden and to get an idea of whether or not these usually very sick patients benefit from the treatment.An internet-based questionnaire was sent out to 24 specialized palliative care units within the Swedish palliative research network. All data were registered by each member directly into a web-based survey generator from which the results were extracted and analyzed.Twenty-two units registered 1,046 patients (median age 68 years, 87% had a cancer diagnosis). Among these patients, 900 were enrolled in advanced home care and the others were treated in in-patient units. Erythrocyte transfusions were given to 174 patients (17%) during the month before registration with a mean amount of 2.9 units (range 1-18) given to each patient. Erythrocyte transfusions were given to 18% of the patients with a malignancy and to 11% of the patients with a non-malignant disease. Six patients also received thrombocyte transfusions. One hundred seventeen patients (68%) were judged to benefit from the erythrocyte transfusions. Eighty-two (58%) of the 141 transfused patients enrolled in advanced home care received their transfusions in their homes. ESAs was given to 127 patients (12%).Transfusions are not uncommon in Swedish palliative care. A majority seemed to benefit from the transfusions. Since they are expensive and time consuming, the effect should, however, be carefully evaluated in every individual in order to avoid ineffective treatment.